A 19-year-old female patient with systemic lupus erythematosus (SLE) who had lupus anticoagulant (LA) and concurrently developed disseminated intravascular coagulation (DIC) during an exacerbation of "central nervous system (CNS) lupus". Since no other indications or causes for DIC could be demonstrated, she was treated with prednisolone and anticoagulants, which rapidly alleviated her DIC condition as well as "CNSlupus". Although abnormalities of coagulation are frequently reported in SLEpatients, DICrarely occurs in patients with SLEwithout associated complications. A review of the pathogenesis of DIC in patients with SLEis discussed. (Internal Medicine 32: 513-517, 1993) 
Introduction
A variety of hematostatic abnormalities such as autoimmunethrombocytopenia and/or abnormalities of the coagulation mechanismshave been knownto be associated in patients with systemic lupus erythematosus (SLE). It has been suggested that activation of local intravascular coagulation occurs and contributes to tissue injury in patients with SLE (1). Antiphospholipid antibodies (aPL), especially lupus anticoagulant (LA) is considered as one of the major causes of abnormalities in the coagulation mechanismsand functions as an inhibitor of the prothrombin-activation complex of the clotting cascade and furthermore reacts with the phospholipid molecules of the vascular endothelial cells and platelets to induce arterial/venous thrombosis (2) .
Disseminated intravascular coagulation (DIC) is characterized as a systemic intravascular microthrombosis and is involved in ischemic organ damage due to the microthrombosis. DIC is often associated with solid tumors, leukemia, septicemia, intravascular hemolysis, liver diseases and obstetrical complications (3) . However, DIC is rarely associated with SLE although minor or low-grade chronic intravascular coagulation abnormalities are frequently observed amongpatients with active SLE (4). Here we report a patient with LA-positive SLEwho developed DIC during an exacerbation of "CNSlupus" and discuss the mechanism of DIC in SLE patients.
Case Report
A 19-year-old high school female patient was diagnosed as having SLE on the basis of arthritis, butterfly rash, pleuritis, On July 23, 1988 , the patient was admitted to our hospital with renal failure due to lupus nephritis. She had generalized edema, bilateral pleural effusions and high blood pressure ( 1 80/ 100 mmHg).Biochemical analysis revealed elevated levels of BUNand creatinine, 1 16 mg/dl and 6.5 mg/dl, respectively. Urinalysis revealed telescoped sediments with 6-12 g/day of proteinuria. GFRwas 6.9 ml/min. Despite steroid "pulse" therapy (methylprednisolone sodium succinate 1000 mg/day for 3 days) and 100 mg/day of azathioprine, oliguria and azotemia progressed. Hemodialysis treatment was commenced from August 5, 1988 . Over the subsequent two years, her condition was stable with hemodialysis treatment and betamethasone in doses of 3^1-mg/ day. From October 8, 1990 , the dose of betamethasone was gradually decreased from 3 mg to 2 mg/day because she had aseptic bone necrosis of both femoral heads and complained of pain at both hip joints even though her SLE condition was @@Tanaka et al stable. Ten days after the dose ofbetamethasone was decreased to 2 mg/day, she developed psychological problems such as crying all day and irritability. No particular causes other than the decrease in the dose of betamethasone could be found for exacerbation of her illness. On November 13, she developed stuporose. There were small petechiae observed on the trunk, purpura and ecchymoticlesions on the extremities and a butterfly rash on her face. The fingers showed multiple small, discrete gangrenous lesions. The laboratory findings are indicated in Fig. 1 . ANAwas 1 :40 and anti-dsDNA antibody was negative. LAwas consistently positive but a marked prolongation of APTT (more than 1 10 second/control 33.6 second) was detected on Nov. 6. Prolonged APTTwas not due to the effect of the anticoagulant used during hemodialysis treatment and drugs associated with the possibly of inducing LAhad not been administered (6) . Anticardiolipin antibody (aCL) (IgG) was 0.6 U (<3.0). Decrease in the levels ofC3 from 41 to 28 mg/dl, C4 from 31 to 28 mg/dl and CH50 from 32.5 to 15.8 U/ml were detected on Nov. 14. small infarctions observed on CT scan of the brain. Retinal vascular narrowing was found by fundscopy but "cytoid bodies", hemorrhage, papillitis and retinal artery thrombosis were not observed. Extensive examinations of the CSF, blood, sputum, urine, the hemodialysis catheter and the dialysis system failed to reveal any evidence of bacterial infection. According to the criteria for DIC (7), the patient satisfied the DIC score in 8 out of 13 points on Nov. 14. Therefore, on the basis of clinical manifestations and laboratory findings, she was diagnosed as having "CNS lupus" and DIC. High-dose steroid therapy (betamethasone 10 mg/day) and anticoagulant therapy with heparin ( 1 0,000 U/day) , nafamostat mesilate (8) (240 mg/day), and AT III (50 ml/day; 10 ml included a dosage of 500 times the amount of AT III present in normal human plasma 1 ml) were administered per day.
Hemodialysis was conducted three times per week. Twodays after commencement of treatment, her consciousness level gradually improved and the levels of FDP, fibrinogen and AT III as well as SGOT, SGPT rapidly improved within 4 days (Fig.  1) . A week later, she had completely recovered from the DIC and "CNS lupus". The decreased C3, C4 and CH50 levels returned to the levels determined on Nov. 6, 2 weeks after the present episode. The brain CTexamination at three weeks after the episode revealed no additional small infarctions and the elevated CSFimmunoglobulin indices returned to within the normal range a monthafter the episode. Over the subsequent 6 months, LA was consistently positive with prolonged APTT levels (42-76 second: control 26-38 second).
Discussion
According to the criteria for DIC proposed by the DIC Research Committee of Japan, Ministry of Health and Welfare, 1981 (7), our patient was diagnosed as DIC. Bleeding symptoms (purpura and ecchymotic lesions), organ (liver) dysfunction, prolonged PT, decreased fibrinogen level and platelet count, increased serum FDPlevel fulfilled the DIC score in 10 out of 13 criteria (score more than 7 is diagnosed as definite DIC). In addition to these findings, the decreased AT III level was a confirmatory finding and very rapid improvement with anticoagulation treatment including heparin confirmed that she had DIC. The transient increase of SGOT,SGPTsuggested that intravascular coagulation occurred in the hepatic arteries since these enzymes normalized within only 5 days by intensive anticoagulant and steroid therapies. Furthermore, a markedly increased level of thrombomodulin (TM) suggested that systemic and extensive endothelial injury occurred during the clinical course (9).
Hemolytic anemia, icterus and appearance of markedly fragmented red blood cells were not observed. Therefore, thrombotic thrombocytopenic purpura (TTP) was not likely associated with this patient. Although the PAIgG level remained within the normal range and antiplatelet antibodies were not detected, the possibility of association of autoimmune thrombocytopenia was not ruled out because bone marrow biopsy and other examinations were not conducted. Thrombotic microangiopathy (TMA)is frequently associated with LA-positive SLE patients (10-12) and slightly elevated levels ofFDP are observed. However, the levels of fibrinogen and AT III are usually observed within the normal range or are slightly elevated in patients with TMA.Therefore, we diagnosed that she had DICbased on the fact that her clinical manifestations and laboratory findings fulfilled the criteria for DIC. Hematological abnormalities in SLE may be due to autoimmunemanifestations, such as circulating anticoagulants, CICs or vasculitis (1, (13) (14) (15) . Although the development ofDIC in SLE is an unusual clinical event, ithas been suggested that an activation of the coagulation system to somedegree occurs in the majority of the patients with active SLE (16).
Evidence supporting this includes an increase in fibrinogen turnover (13) and FDP (1), elevated levels of fibrinopeptide A (13) and thrombomodulin (TM) which is released due to the injury of vascular endothelial cells as is observed in patients with SLE as well as DIC (9) . Only ll cases ofSLE associated with DIC without any complications which usually induce DIC , have been reported to date (6, (17) (18) (19) (20) (21) (22) (23) . In these reports, vascular involvement was found in most cases, and the patients had severe clinical manifestations (Table 1) . Amongthese 1 1 cases, 3 out of6 cases were positive for circulating anticoagulants; one case was positive for aCL (6) and the type of circulating anticoagulants was not described for the remaining 2 cases (1 8, 21) . Although there has been no report of patients with LAdeveloping DIC, it may be possible that the circulating anticoagulants including LA and/or aCL may induce DIC. Cerebral infarction or cerebral ischemic attack often occurs in patients with "antiphospholipid syndrome" (24) . However, the loss of consciousness in this patient is unlikely due to transient ischemic attack or lacunar stroke which was induced by LA, DIC or both since the immunoglobulin indices in CSF were markedlyelevated at the onset of loss of consciousness. It has been reported that an increase in the level of immunoglobulin indices in CSFis more frequently detected in patients with neuropsychiatric manifestation than in patients with cerebrovascular accidents (25) . Moreover, additional new low à"density spots were not detected on the brain CT scan examined during the 3rd week after the episode. Although vasculitis associated with exacerbation of SLE could not be completely ruled out, the levels of protein and cells of CSF are usually elevated in vasculitis. This evidence strongly suggests that the loss of consciousness was not due to cerebral thrombosis but due to the so called "CNSlupus" (neuropsychiatric lupus) in which polyclonal B cell activation occurred in the central nervous system and the neuron-reactive antibodies in CNS might have been involved (25, 26) . Due to the fact that the present patient had a recurrence of "CNSlupus" immediately prior to the development of DIC and showedno evidence of bacterial infection or other complications which maycause DIC, we considered that the occurrence of DICwas possibly related to the exacerbation of SLE in this case.
The pathogenesis of DIC in SLE patients is not fully understood. Vasculitis has been considered to be involved in the (27) . Complementand platelet activation have been postulated as explanations for coagulation systemactivation in the setting of vasculitis (27) (28) (29) . LA and aCL are responsible for the local intravascular coagulation. Although circulating anticoagulant has been demonstrated in only a few cases of SLE associated with DIC, our hypothetical view of this case is that LAmay have been involved, in one wayor another, in the occurrence ofDIC due to the fact that a markedly prolonged APTTwas detected prior to the onset of DIC without an increase of CIC. Massive production of LA during the exacerbation of SLE may have led to extensive and systemic injury of endothelial cells which might have triggered the development of DIC. Despite the presence of vasculitis and FDP, DIC is not frequently mentioned in the extensive analysis of SLE. A higher index of suspicion may reveal the true incidence and pathogenesis of DIC in patients with SLE.
